This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Freeline Therapeutics Holdings Crescita futura
Future criteri di controllo 5/6
Freeline Therapeutics Holdings is forecast to grow earnings and revenue by 60.7% and 52.7% per annum respectively while EPS is expected to grow by 75.9% per annum.
Informazioni chiave
60.7%
Tasso di crescita degli utili
75.9%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 28.8% |
| Tasso di crescita dei ricavi | 52.7% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 15 Dec 2023 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 62 | 16 | 3 | 3 | 1 |
| 12/31/2025 | 21 | 12 | 0 | 0 | 2 |
| 12/31/2024 | N/A | -21 | -23 | -23 | 2 |
| 12/31/2023 | 0 | -76 | -66 | -65 | 2 |
| 9/30/2023 | 1 | -50 | -69 | -64 | N/A |
| 6/30/2023 | 1 | -53 | -77 | -71 | N/A |
| 3/31/2023 | N/A | -61 | -77 | -70 | N/A |
| 12/31/2022 | N/A | -89 | -85 | -78 | N/A |
| 9/30/2022 | N/A | -101 | -79 | -76 | N/A |
| 6/30/2022 | N/A | -117 | -86 | -83 | N/A |
| 3/31/2022 | N/A | -132 | -102 | -100 | N/A |
| 12/31/2021 | N/A | -140 | -112 | -108 | N/A |
| 9/30/2021 | N/A | -144 | -129 | -124 | N/A |
| 6/30/2021 | N/A | -138 | -136 | -132 | N/A |
| 3/31/2021 | N/A | -115 | -115 | -111 | N/A |
| 12/31/2020 | N/A | -96 | -97 | -95 | N/A |
| 9/30/2020 | N/A | -73 | -73 | -72 | N/A |
| 6/30/2020 | N/A | -63 | -53 | -51 | N/A |
| 3/31/2020 | N/A | -58 | -57 | -54 | N/A |
| 12/31/2019 | N/A | -54 | -55 | -52 | N/A |
| 12/31/2018 | N/A | -33 | -30 | -26 | N/A |
| 9/30/2017 | N/A | -17 | -20 | -19 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: FRLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Guadagni vs Mercato: FRLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: FRLN is expected to become profitable in the next 3 years.
Ricavi vs Mercato: FRLN's revenue (52.7% per year) is forecast to grow faster than the US market (8.2% per year).
Ricavi ad alta crescita: FRLN's revenue (52.7% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if FRLN's Return on Equity is forecast to be high in 3 years time